Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics to $80 from $61 and keeps an Equal Weight rating on the shares post the Q4 report. The Q4 update largely incremental, with on-track pipeline progress, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRSP:
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Crispr Therapeutics options imply 7.2% move in share price post-earnings
- CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
- Crispr Therapeutics initiated with a Peer Perform at Wolfe Research
- Cathie Wood’s ARK Investment bought 280K shares of Crispr Therapeutics today